Chronic Pancreatitis

Meet the patient

A 48-year-old man who drinks most of a bottle of spirits every evening is sitting forward over the bedside table at 3am, gripping his abdomen. The pain is epigastric, boring straight through to his spine, and it has been coming and going for months. Over the last three months his stools have turned bulky, pale and oily — they float and will not flush — and a clinic check last week found a random glucose of 14. He has lost 12 kg. A plain abdominal film shows speckled calcification laid across the pancreas.[1]

The registrar is not really being asked 'what is this?' — a cachectic drinker with calcification, oily stools and new diabetes is unmistakable. The questions that decide his care are three: what has destroyed his pancreas, how much function is left, and is a cancer hiding inside it. Hold those three and the whole topic slots into place.[1]

Irreversible — the one word that separates chronic from acute

Chronic pancreatitis is a progressive, fibro-inflammatory disease that leaves irreversible structural damage and permanent loss of both exocrine and endocrine function. Fibrosis replaces acinar cells, protein plugs calcify into stones, ducts distort and strictures form — and once the tissue is gone it does not regenerate.[1][2]

That single word — irreversible — is the whole distinction from acute pancreatitis. A mild interstitial acute pancreatitis resolves completely and the gland recovers; chronic pancreatitis does not. The two are still kin: recurrent acute pancreatitis is now recognised as a driver of chronic disease (the SAPE model — Sentinel Acute Pancreatitis Event), and an acute flare can still land on top of an already-chronic gland.[2]

The classic trap: a heavy drinker re-presenting with epigastric pain and a raised amylase is labelled 'another acute pancreatitis'. Once calcification, ductal change or exocrine failure appear, it is chronic — the episode on top is a flare, not the whole story. The practical pay-off is that a chronic gland cannot be 'rested' back to health; you are managing permanent loss, not waiting for recovery.[1]

The mantra for this topic: irreversible — that one word separates chronic from acute.[1]

TIGAR-O — name the cause

Chronic pancreatitis is classified three ways — by aetiology (TIGAR-O), by combined risk factors (M-ANNHEIM), and by morphology — and the final-prof examiner wants all three. TIGAR-O is the one to open any aetiology answer with; M-ANNHEIM scores severity once the cause is named.[2][4]

[4]

M-ANNHEIM is the unifying risk-factor and severity system — it bundles Multiple factors together (Alcohol, Nicotine, Nutritional, Hereditary, Efferent duct, Immunological, Metabolic and miscellaneous) and combines them with clinical course, imaging and function to grade mild, moderate and marked disease. Reach for it when the stem asks you to stage chronic pancreatitis, not just name its cause.[4]

By morphology, four patterns appear — and the morphology predicts the management:[1]

• Calcifying — the commonest form (alcoholic, tropical, hereditary). Protein plugs calcify into stones, the duct dilates, and strictures alternate with dilatation to give the classic 'chain of lakes' on ERCP.
• Non-calcifying (obstructive) — a discrete ductal obstruction (tumour, stricture, divisum); the duct dilates upstream of the block, calcification is sparse, and the change reverses if the obstruction is relieved.
• Autoimmune — diffuse 'sausage-shaped' enlargement with a capsule-like rim and an IgG4-positive infiltrate; steroid-responsive.
• Tropical calcific — early-onset, large ductal calculi, severe diabetes, in southern India.[1]

[1] [3] [5]

How common, and why southern India breaks the curve

Chronic pancreatitis is uncommon but not rare. Western prevalence is about 30 to 40 per 100,000, with an incidence of 4 to 13 per 100,000 per year. Alcoholic CP shows a male-to-female ratio of 4 to 5 to 1 and presents in the 40s to 50s; idiopathic CP is more evenly split and divides into early-onset (mean age 20) or late-onset (mean age 60).[3]

The regional epidemiology is striking, and it is exam gold. In southern India (Kerala), the prevalence of tropical calcific pancreatitis reaches over 100 per 100,000 — some series report 114 to 200 per 100,000 — and fibrocalculous pancreatic diabetes was once a major cause of diabetes in young Indians. Any young, thin diabetic from that region with large ductal stones has chronic pancreatitis until proven otherwise.[1][3]

The southern-Indian excess is attributed to cassava (tapioca) cyanogenic-glycoside exposure, chronic protein-calorie malnutrition, and a high prevalence of SPINK1 N34S mutations — not to alcohol, which is the dominant cause everywhere else.[1][5]

The cassava hypothesis — why it still gets asked

Cassava roots contain linamarin, a cyanogenic glycoside; chronic dietary exposure (especially with protein deficiency and depleted sulphur donors needed to detoxify cyanide to thiocyanate) is proposed to generate chronic oxidative pancreatic injury in a malnourished host. The hypothesis is contested and never proven, but it remains a named viva answer for the tropical calcific phenotype alongside the SPINK1 N34S association.[5]

The risk factors and the aetiology they favour:[1]

| Risk factor | Aetiology favoured |[1] |---|---| | Alcohol (over 60 to 80 g/day for over 5 to 10 years) | Toxic-metabolic (commonest overall) | | Tobacco smoking | Independent co-factor; accelerates calcification and progression; multiplies alcohol risk | | Young onset / family history | Hereditary (PRSS1, SPINK1), tropical | | Recurrent AP attacks | Recurrent-and-severe-AP (SAPE) pathway | | Hypercalcaemia, hypertriglyceridaemia | Toxic-metabolic | | Pancreatic mass / divisum / trauma | Obstructive | | Older man and jaundice and raised IgG4 | Autoimmune type 1 |

[1] [5]

The pancreatic stellate cell — the one cell that builds the fibrosis

Every aetiological road converges on a single effector cell: the pancreatic stellate cell (PSC). The cause names the disease; the stellate cell makes it permanent.[2]

In health, PSCs are quiescent, vitamin-A (retinoid)-storing periacinar cells. In chronic pancreatitis they are activated by alcohol, acetaldehyde, oxidative stress and cytokines (TGF-beta, PDGF, IL-1, TNF-alpha, IL-6) into myofibroblast-like cells that synthesise and deposit collagen types I and III, fibronectin and matrix proteins. Persistent PSC activation produces the dense fibrosis, acinar loss and ductal distortion that are the histological signature of the disease — and the reason it is irreversible.[2]

The four mechanistic hypotheses — how the gland is destroyed

Four non-exclusive mechanisms have been proposed, and all converge on the stellate cell. Toxic-metabolic: alcohol, acetaldehyde and CYP2E1-derived free radicals directly injure acinar cells — explaining why only a minority of heavy drinkers ever develop CP. Oxidative stress: ethanol-induced CYP2E1 generates reactive oxygen species that overwhelm glutathione, causing lipid peroxidation and periductal fibrosis — the rationale (now refuted by ANTICIPATE) for antioxidant therapy. Necrosis-fibrosis (the SAPE sequence): repeated, often silent, focal necrosis heals by collagen, linking recurrent acute pancreatitis to chronic disease. Ductal or obstructive: plugs and stones raise intraductal pressure and cause upstream atrophy — and this form reverses if the obstruction is relieved.[2][6]

Why it hurts — four parallel pain pathways

Pain in chronic pancreatitis is multifactorial — and naming the pathway chooses the treatment. Roughly 85 to 90 percent of patients hurt; in 10 to 15 percent the disease is painless.[1]

• Ductal hypertension — stones, strictures and proteinaceous plugs obstruct the main pancreatic duct, raising intraductal pressure. Relieved by ESWL, stenting or surgical drainage (Puestow).
• Parenchymal / compartment hypertension — the fibrotic, non-compliant capsule raises interstitial pressure, producing a form of pancreatic compartment syndrome. Relieved by decompression or resection.
• Perineural inflammation — CP nerves are increased in number and diameter, surrounded by immune-cell (eosinophil) infiltrates, and exposed to nerve growth factor (NGF) and inflammatory cytokines. This is the neuropathic, opioid-preferring component, partially addressed by neuromodulators.
• Ischaemia — microvascular compromise from fibrosis.[1]

The 10 percent line — why steatorrhoea is always late

Steatorrhoea appears only when pancreatic lipase secretion falls below 10 percent of normal — that is, when over 90 percent of acinar reserve is already gone. The pancreas has an enormous functional reserve, which is exactly why malabsorption is a late and never an early sign.[1]

Everyone forgets this: a normal faecal elastase in early disease does not exclude chronic pancreatitis. The gland can be heavily fibrosed and still digest fat, until the last 10 percent of reserve tips over.[1]

The endocrine loss is just as distinctive. Type 3c (pancreatogenic) diabetes follows destruction of both beta-cells (insulin) and alpha-cells (glucagon) — and losing glucagon is what makes it dangerous. With no glucagon counter-regulation, the diabetes is brittle and hypoglycaemia-prone, often needing insulin at lower doses than type 1 (residual beta-cell mass plus hepatic and peripheral insulin resistance) but swinging unpredictably. Type 3c accounts for 5 to 10 percent of all diabetes in Western series and far more where tropical calcific pancreatitis is prevalent.[1]

The classic triad — and the order it arrives in

The classic picture is the triad of recurrent epigastric pain radiating to the back, steatorrhoea, and diabetes with weight loss — but the order and completeness of the triad vary with the aetiology and the stage. Pain comes first; steatorrhoea and diabetes come late, as reserve collapses.[1]

Pain (85 to 90 percent of patients): epigastric, radiating through to the back, eased by sitting forward; post-prandial, lasting hours to days and often alcohol-precipitated; relapsing-remitting early, becoming continuous in advanced disease. In 10 to 15 percent the disease is painless, presenting only as diabetes, steatorrhoea or weight loss.[1]

Exocrine insufficiency — steatorrhoea and malabsorption:[1]

• Bulky, pale, foul-smelling, oily stools that are difficult to flush and leave an oil ring in the pan — steatorrhoea is faecal fat over 7 g/day.
• Weight loss, anorexia, bloating, flatulence, and fat-soluble vitamin deficiency (A, D, E, K) — easy bruising (K), night blindness (A), osteomalacia (D), ataxia or neuropathy (E).
• B12 deficiency (impaired R-protein cleavage) and calcium, magnesium, zinc deficiency.[1]

Endocrine insufficiency — type 3c diabetes: polyuria, polydipsia and weight loss, but with a tendency to severe hypoglycaemia because glucagon counter-regulation is lost; often insulin-requiring but at lower doses than type 1.[1]

The exam-tested exceptions — when the triad is absent or scrambled:[1][7]

• Painless CP — new diabetes, steatorrhoea or weight loss; calcification found incidentally.
• Elderly — only cachexia and unexplained weight loss, or presenting as pancreatic cancer (which must always be excluded).
• Tropical calcific CP — young, thin patient from southern India or Africa with early severe diabetes and large ductal stones.
• Autoimmune pancreatitis — painless obstructive jaundice in an older man, mimicking pancreatic cancer.
• Hereditary pancreatitis — recurrent AP from childhood with a positive family history.[1][7]

[1]

At the bedside, look for the consequences of chronic gland failure and chronic pain:[1]

• Cachexia, temporal wasting, low BMI, muscle wasting (sarcopenia).
• Jaundice (common bile duct stricture in head disease; cholangitis if infected).
• Epigastric tenderness — often surprisingly mild relative to the reported pain.
• Palpable mass — a pseudocyst or inflammatory head mass.
• Erythema ab igni — reticular brown or purple discolouration of the abdominal skin from chronic heat-pad application: a classic exam-favourite bedside sign of chronic pancreatic pain.
• Splenomegaly suggests splenic vein thrombosis (left-sided portal hypertension).
• Signs of chronic liver disease, injection marks and stigmata of chronic opioid use.[1]

Two named traps — the cancer mimic and the vascular one

Two mimics decide whether your patient lives or dies, and both are high-yield viva territory: autoimmune pancreatitis (the cancer mimic) and splenic vein thrombosis (the vascular trap). Name them before the examiner does.[1][7]

The cancer mimic — autoimmune pancreatitis (type 1, IgG4). An older man presents with painless obstructive jaundice, weight loss, and a mass on imaging — every feature of pancreatic cancer, except the gland is diffusely enlarged and 'sausage-shaped' with a capsule-like rim, the serum IgG4 is raised, and there is other-organ involvement (bile-duct strictures, retroperitoneal fibrosis, renal lesions, salivary or lacrimal enlargement). It is dramatically steroid-responsive, diagnosed by HISORt criteria, and fundamentally curable — which is why missing it (and sending the patient to palliative cancer care) is the worst error in the topic.[1][2]

The vascular trap — splenic vein thrombosis. Chronic peripancreatic inflammation thromboses the splenic vein and backs blood up into the left (sinistral) side of the portal system — sinistral is Latin for left — producing isolated gastric fundal varices with a normal liver and no oesophageal varices. A CP patient bleeding from fundal varices is bleeding from this, not from cirrhosis, and splenectomy is curative. That single operation is the answer the examiner is waiting for.[1]

The broader differential of epigastric pain with weight loss, or steatorrhoea with diabetes:[1][7]

[1] [4] [7]

Always specifically exclude pancreatic cancer and autoimmune pancreatitis when the presentation, epidemiology or imaging is atypical — both fundamentally change management.[1][7]

No gold standard — combine a picture with a function

There is no single gold-standard test for chronic pancreatitis. Diagnosis rests on a combination of structural imaging (calcification, ductal change, atrophy) and functional testing (exocrine insufficiency). Early disease may have normal imaging and normal function, which is why early CP is genuinely hard to prove.[1][2]

Functional tests (exocrine reserve):[1]

• Faecal elastase-1 — the first-line non-invasive test. It is stable in stool and not affected by pancreatic enzyme replacement therapy (an advantage over faecal chymotrypsin). Cut-offs: under 200 microg/g = exocrine insufficiency (moderate); under 100 microg/g = severe. Sensitivity is poor in early disease.
• Secretin stimulation test — the most sensitive direct function test for early CP (duodenal tube, IV secretin, measure bicarbonate output); invasive, specialist-centre only.
• 72-hour faecal fat — historical; confirms steatorrhoea (over 7 g/day) but does not localise the cause.
• BT-PABA, pancreolauryl, faecal chymotrypsin — older indirect tests, largely superseded by faecal elastase.[1]

Structural imaging:[1][7]

• Abdominal X-ray — pancreatic calcification is pathognomonic when present and is seen in 30 to 50 percent of cases (more in alcoholic and tropical CP). Cheap, fast, the exam-favourite first test.
• Ultrasound — first-line cross-sectional; shows ductal dilation, calcification, pseudocyst, gallstones; limited by habitus and bowel gas.
• Contrast CT pancreas — the most useful single structural test: parenchymal calcification, dilated main duct, atrophy, pseudocysts, inflammatory masses, vascular complications, and it excludes cancer. Graded by the Cambridge classification.
• MRCP / secretin-MRCP — best non-invasive ductal imaging; secretin enhancement improves sensitivity for early disease.
• Endoscopic ultrasound (EUS) — most sensitive for early or equivocal disease, using the Rosemont criteria.
• ERCP — once the diagnostic gold standard (the 'chain of lakes' or 'string of pearls' from alternating strictures and dilatation), now used predominantly therapeutically because of post-ERCP pancreatitis risk.[1][7]

[1]

Adjunctive bloods round out the work-up: glucose and HbA1c (type 3c diabetes, often low C-peptide), serum IgG4 and other-organ assessment for autoimmune disease, fat-soluble vitamins (A, D, E, K), B12, folate, calcium, magnesium, zinc for malabsorption, bone profile and DEXA for osteoporosis or osteomalacia, genetic testing (PRSS1, SPINK1, CFTR, CTRC, CPA1) in young-onset, familial, tropical or idiopathic disease, and CA 19-9 with EUS-FNA to exclude cancer in any mass.[5][7]

For autoimmune pancreatitis, reproduce the HISORt criteria verbatim:[2]

| HISORt | Criterion |[1] |---|---| | Histology | Lymphoplasmacytic sclerosing pancreatitis, storiform fibrosis, abundant IgG4-positive cells | | Imaging | Diffuse enlargement ('sausage' gland), capsule-like rim, narrowed main pancreatic duct | | Serology | Raised serum IgG4 (over 135 mg/dL) | | Other organ involvement | Bile-duct strictures, retroperitoneal fibrosis, renal lesions, salivary or lacrimal enlargement, lymphadenopathy | | Response to therapy | Dramatic regression with corticosteroids |

[2]

The diagnosis is made by a combination of these features; a steroid trial is both diagnostic and therapeutic when imaging and serology are suggestive — but exclude cancer first where the picture is not secure.[1]

Treat four consequences — pain, enzymes, insulin, complications

[1]

Definitive management is multidisciplinary and targets the four consequences of chronic pancreatitis: pain, exocrine insufficiency, endocrine insufficiency, and complications. Work the tiers in order.[1][2]

Tier 1 — correctable causes and conservative measures (start here)

• Complete abstinence from alcohol slows progression, reduces flares and improves survival — provide structured withdrawal support, thiamine, and addiction-medicine input.
• Smoking cessation carries an independent benefit.
• Pancreatic enzyme replacement (PERT) treats exocrine insufficiency and modulates pain (it feedback-inhibits CCK-mediated pancreatic stimulation). Pancreatin (Creon) 25,000 to 40,000 units of lipase with each main meal, and 10,000 to 25,000 units with snacks, titrated to a maximum of about 75,000 to 80,000 units per meal, with a PPI (omeprazole 20 to 40 mg daily, or pantoprazole 40 mg daily) or H2-antagonist (ranitidine is withdrawn in many regions — use famotidine 20 mg 12-hourly) to protect the enzymes from gastric-acid degradation. Take it WITH food, throughout the meal — never before or after.
• Diet — small, frequent, low-fat, high-protein meals; MCT oil; fat-soluble vitamins (A, D, E, K); calcium and vitamin D.[1]

Stepwise analgesia — the WHO ladder, with modern corrections

• Paracetamol 1 g orally 6-hourly (max 4 g/day) first.
• Then an NSAID — ibuprofen 400 mg 8-hourly or naproxen 500 mg 12-hourly, with caution for gastric and renal harm in the malnourished alcoholic.
• Then a weak opioid — tramadol 50 to 100 mg orally 4 to 6-hourly (preferred over codeine for less constipation).
• Then a strong opioid — morphine 5 to 10 mg orally 4-hourly, a fentanyl transdermal patch 12 to 100 microg/h for chronic stable pain, or methadone in specialist hands.
• Morphine is now acceptable — the old preference for pethidine (meperidine) to avoid sphincter of Oddi spasm is obsolete, and pethidine's metabolite (norpethidine) causes seizures in chronic use.
• Neuromodulators for the neuropathic component — pregabalin 75 to 300 mg 12-hourly, gabapentin 300 to 1200 mg 8-hourly, amitriptyline 10 to 25 mg at night.
• Early PERT for pain — start it before escalating opioids.[1]

Tier 2 — endoscopic therapy

• Extracorporeal shock-wave lithotripsy (ESWL) — first-line for large (over 5 mm) calcified pancreatic-duct stones; fragments them for passage or extraction, often combined with ERCP and sphincterotomy.
• Sphincterotomy and stricture dilation or stenting — single plastic stent first, multiple or fully-covered self-expanding metal stents for refractory benign strictures.
• Endoscopic pseudocyst drainage (EUS-guided cystgastrostomy).[1]

Tier 3 — surgery, chosen by duct size and head disease

[1] [7]

Celiac plexus block or neurolysis (EUS- or CT-guided steroid plus or minus bupivacaine or neurolytic) and thoracoscopic splanchnicectomy are third-line for refractory pain when endoscopic and surgical options are exhausted; benefit is typically short-lived.[1]

Type 3c (pancreatogenic) diabetes

• Insulin is usually required, but doses are often lower than in type 1 (residual beta-cell mass plus hepatic insulin resistance). The dominant risk is severe hypoglycaemia from lost glucagon counter-regulation — warn and monitor, individualise targets.
• Metformin may be added if an insulin-resistance component is present and tolerated.
• Avoid sulfonylureas (hypoglycaemia), GLP-1 agonists and DPP-4 inhibitors (pancreatitis concerns); caution with SGLT2 inhibitors (euglycaemic ketoacidosis).[1]

Autoimmune pancreatitis — corticosteroids

• Prednisolone 0.6 to 1 mg/kg/day (typically 40 mg daily) for 2 to 4 weeks, then a gradual taper over weeks to months; the radiological response is typically dramatic (the gland shrinks, the mass regresses, jaundice resolves).
• Type 1 relapses frequently (over 50 percent) and may need maintenance azathioprine, mycophenolate, rituximab or low-dose steroids; type 2 relapses less.
• Always exclude pancreatic cancer (biopsy or EUS-FNA) before committing to a steroid trial when the diagnosis is not secure.[1]

Complications — what to do when they arrive

• Pseudocyst — observe if asymptomatic and under 6 cm; drain (endoscopic EUS-guided cystgastrostomy first-line) if symptomatic, infected, over 6 cm, or persisting beyond 6 weeks (when the wall is mature).
• Biliary obstruction — endoscopic stenting for common-bile-duct strictures; surgical bypass if refractory.
• Splenic vein thrombosis with isolated gastric varices — splenectomy is curative.
• Visceral pseudoaneurysm (splenic, gastroduodenal) — urgent mesenteric angiography and coil embolisation; may need surgery.[1]

Antioxidants — a refuted hypothesis (the ANTICIPATE lesson)

The oxidative-stress hypothesis once drove routine antioxidant supplementation (mixtures of selenium, beta-carotene, vitamin C, vitamin E, methionine). The early, smaller Kirk 2006 trial suggested reduced pain and improved quality of life, and for a while this was standard advice.[8]

Then the definitive multicentre randomised ANTICIPATE trial (Siriwardena 2012, Gastroenterology) showed that antioxidants did NOT reduce pain in chronic pancreatitis — and most guidelines moved away from routine supplementation. The lesson for the viva: do not recommend antioxidants as a pain treatment; name the trial that killed it.[6]

The classic trap: a candidate who answers 'antioxidants' to a chronic-pancreatitis pain stem is quoting 2006. The 2012 answer is that they do not work.[6]

Region-aware subtypes — the ones that change the answer

Tropical calcific pancreatitis / fibrocalculous pancreatic diabetes (FCPD) — onset under 30 years in southern India, Africa and Asia; low BMI and malnutrition; large, dense intraductal calculi; early, severe, insulin-requiring diabetes (FCPD, under the type 3c umbrella); the cassava (cyanogenic glycoside) hypothesis and a high prevalence of the SPINK1 N34S mutation; and a high pancreatic-cancer risk. This is the region-aware exam gold — a young, thin, diabetic Indian with pancreatic stones is tropical calcific pancreatitis until proven otherwise.[1][5]

• Hereditary pancreatitis — PRSS1 (cationic trypsinogen), autosomal dominant, penetrance about 80 percent; recurrent AP from childhood (under 20 years); a family history of CP or pancreatic cancer; lifetime pancreatic-cancer risk around 40 percent by age 70; surveillance with EUS or MRCP from age 40, or 20 years after onset.[5]
• Autoimmune pancreatitis type 2 — no IgG4 elevation, association with inflammatory bowel disease (especially Crohn's or ulcerative colitis), younger patients, equally steroid-responsive, lower relapse.
• Obstructive CP — discrete ductal obstruction by tumour, pancreas divisum with papillary stenosis, post-traumatic stricture, or ascariasis in endemic regions; reverses if the obstruction is relieved.
• Groove (paraduodenal) pancreatitis — inflammation in the pancreaticoduodenal groove with cystic dystrophy of the duodenal wall, in young men with heavy alcohol use; mimics pancreatic head cancer.[1]

Complications — the preventable-harm list

The complications of chronic pancreatitis are where patients are actually lost, and most are preventable or treatable. Name them in order of frequency and danger.[1][7]

• Pain — the commonest and most disabling; the commonest iatrogenic sequel is opioid dependence and narcotic bowel syndrome.
• Pancreatic pseudocyst — 10 to 30 percent; an infected pseudocyst is a pancreatic abscess.
• Bile-duct stricture — distal CBD obstruction from fibrosis or head mass, giving obstructive jaundice, cholangitis, secondary biliary cirrhosis if chronic.
• Duodenal obstruction — fibrosis or inflammatory mass in the head causing gastric-outlet obstruction.
• Pancreatic fistula — a disrupted duct causing pancreatic ascites or a chronic pleural effusion (very high amylase in the fluid); managed by NPO, octreotide, ERCP and stenting, or surgery.
• Splenic vein thrombosis — left-sided (sinistral) portal hypertension and isolated gastric fundal varices; splenectomy is curative.
• Visceral pseudoaneurysm (splenic, gastroduodenal, pancreatic) — may erode into a duct or pseudocyst for a catastrophic, life-threatening GI bleed; urgent angiography and embolisation.
• Metabolic and nutritional — fat-soluble vitamin deficiency, osteoporosis, osteomalacia, sarcopenia, recurrent hypoglycaemia.
• Pancreatic cancer — cumulative risk about 4 percent at 20 years, higher in hereditary, tropical and smoking CP; any new pain, weight loss or sudden-onset diabetes triggers a search.[1][7]

Prognosis — and the painful paradox

Chronic pancreatitis is progressive and shortens life expectancy by about 10 to 20 years. The dominant causes of death are diabetes, malnutrition, opioid and alcohol addiction, pancreatic cancer, and cardiovascular disease.[1][3]

Poor prognostic factors: continued alcohol and tobacco use, low BMI and continued weight loss, young age at onset, hereditary or tropical subtype, the presence of calcification, and low social support.[1]

Consultant confession — the painful paradox: pain often diminishes or 'burns out' in very advanced disease as the gland destroys itself — but only at the cost of complete exocrine and endocrine failure. Never sell that to a patient as a treatment goal.[1]

Structured annual review covers pain, glucose and HbA1c, nutrition (weight, BMI, micronutrients, faecal elastase), fat-soluble vitamins, bone density (DEXA), PERT adequacy and adherence; in hereditary and other high-risk subtypes, pancreatic-cancer surveillance with EUS or MRCP begins at the appropriate age.[7]

The framework is globally consistent, but resource and aetiology drive regional deltas:[1]

[1]

Special populations

• Children — CP is rare; consider hereditary (PRSS1), autoimmune, and tropical causes. Emphasise genetic testing, growth and nutrition, PERT and fat-soluble-vitamin replacement, and avoid opioids where possible; TPIAT is increasingly used for hereditary intractable disease.
• Pregnancy — optimise nutrition and glycaemic control before and during pregnancy; prefer non-opioid analgesia (paracetamol, low-dose tramadol) and reserve opioids for severe flares; time elective drainage or surgery for the postpartum period. PERT and insulin are safe in pregnancy.
• Elderly — atypical, often painless presentation with weight loss and new diabetes; lower threshold to image and to exclude pancreatic cancer; mind renal function and polypharmacy when dosing analgesia and PERT.
• Malnourished and alcoholic patient — thiamine 100 mg daily, B-complex, folate, refeeding-syndrome precautions (monitor phosphate, potassium, magnesium), fat-soluble vitamins, compression stockings and DVT prophylaxis for the immobile.
• The patient already on long-term opioids — multimodal analgesia, addiction-medicine input, consider TPIAT in carefully selected intractable small-duct disease.[1][7]

The run-down and the mantra

[4]

The mantra: irreversible — that one word separates chronic from acute. Name the cause with TIGAR-O, prove the loss with imaging plus faecal elastase, treat the four consequences in tiers, and never miss cancer, autoimmune, or the splenic-vein varices.[1]

Ward-round test — three stems, thirty seconds each

Stem 1 — the man from the top of the topic (answer)

The 48-year-old drinker with epigastric pain boring to the back, oily floating stools, a random glucose of 14, 12 kg weight loss, and speckled calcification on the abdominal film. Confirm the diagnosis, name the first test of function, and give the first treatment with a dose. Model: This is chronic pancreatitis — the classic triad plus calcification, which is pathognomonic on AXR. The first functional test is faecal elastase-1 (under 200 microg/g confirms exocrine insufficiency and is unaffected by enzyme therapy). First treatment: confirm abstinence from alcohol and smoking, start pancreatin 25,000 to 40,000 units lipase with each main meal and 10,000 to 25,000 with snacks, with a PPI, taken with food throughout the meal, and begin stepwise analgesia (paracetamol 1 g 6-hourly, then NSAID, then tramadol 50 to 100 mg 4 to 6-hourly) with a neuromodulator for the neuropathic component. Screen for pancreatic cancer if there is any mass or new-onset diabetes pattern.[1]

Stem 2 — the fundal-variceal bleed (answer)

A patient with known chronic pancreatitis presents with an upper-GI bleed. OGD shows isolated gastric fundal varices; liver synthetic function and platelets are normal; there are no oesophageal varices. What happened, and what cures it? Model: This is splenic vein thrombosis from chronic peripancreatic inflammation causing left-sided (sinistral) portal hypertension with isolated gastric fundal varices — a normal liver, no oesophageal varices, and a diseased pancreas is the signature. The definitive, curative treatment is splenectomy. Do not reach for liver-directed variceal therapy; this is a pancreatic vascular problem.[1]

Stem 3 — the painless jaundice and the sausage gland (answer)

A 68-year-old man has painless obstructive jaundice, weight loss, and a diffusely enlarged 'sausage-shaped' pancreas with a capsule-like rim on CT. Serum IgG4 is markedly raised; he also has a retroperitoneal soft-tissue mass. What is the diagnosis, how do you confirm it, and what is the first drug — and what must you exclude first? Model: This is type 1 autoimmune pancreatitis (IgG4-related disease), the steroid-responsive mimic of pancreatic cancer. Confirm with the HISORt criteria (histology, imaging, serology, other-organ involvement, response to therapy) — here imaging plus serology plus other-organ involvement already satisfy it. Before any steroid, exclude pancreatic cancer with EUS-FNA or biopsy where the picture is not fully secure, because steroids will mask but not treat a cancer. Then start prednisolone 0.6 to 1 mg/kg/day (typically 40 mg daily) for 2 to 4 weeks and plan a gradual taper; expect a dramatic radiological response and warn that type 1 relapses frequently (over 50 percent).[1][2]

References

1. [1]Majumder S, Chari ST. Chronic pancreatitis Lancet, 2016.PMID 26948434
2. [2]Kleeff J, Whitcomb DC, Shimosegawa T, et al. Chronic pancreatitis Nat Rev Dis Primers, 2017.PMID 28880010
3. [3]Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer Gastroenterology, 2013.PMID 23622135
4. [4]Schneider A, Löhr JM, Singer MV The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease J Gastroenterol, 2007.PMID 17351799
5. [5]Whitcomb DC. Genetics of alcoholic and nonalcoholic pancreatitis Curr Opin Gastroenterol, 2012.PMID 22885947
6. [6]Siriwardena AK, Mason JM, Sheen AJ, Makin AJ, Shah NS. Antioxidant therapy does not reduce pain in patients with chronic pancreatitis: the ANTICIPATE study Gastroenterology, 2012.PMID 22683257
7. [7]Kirkegård J, Mortensen FV, Cronin-Fenton D Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis Am J Gastroenterol, 2017.PMID 28762376
8. [8]Kirk GR, White JS, McKie L, Stevenson M, Young I, Clements WJ, et al. Combined antioxidant therapy reduces pain and improves quality of life in chronic pancreatitis J Gastrointest Surg, 2006.PMID 16627214